EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Evaluation of the safety of PD ‐1/ PD ‐ L1 inhibitors for immunotherapy in patients with malignant tumors after COVID ‐19 infection: A single‐center cohort study

Kaili Liao, Jinting Cheng, Yujie Hu, Beining Zhang, Peng Huang, Jie Liu, Wenyige Zhang, Huan Hu, Xinyi Bai, Yihui Qian, Daixin Guo, Kun Ai und 2 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70202 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Kaili Liao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, Immune Checkpoint Inhibitors, SARS-CoV-2. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

An increasing body of evidence suggests a close association between COVID‐19 infection and the safety of PD‐1/PD‐L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory. Material and Methods We conducted a retrospective analysis of cancer patients who received PD‐1/PD‐L1 inhibitor therapy at the same institution from November 2022 to May 2023. After excluding patients with missing information, a total of 224 cases were included. In our study, immune‐related adverse events (irAEs) that occurred during the hospitalization of patients were included in the analysis. Further analysis of inter‐subgroup differences was conducted following a 1:2 propensity score matching. Statistical analyses were performed using the Fisher's exact, chi‐squared, and Mann–Whitney U ‐tests.

Result

The results showed that no statistically significant differences between the two subgroups in the incidence of irAEs, changes in immune function before and after using PD‐1/PD‐L1 inhibitors, and alterations in hepatic and renal function ( p > 0.05).

Conclusion

Our findings suggest that infection with COVID‐19 does not significantly impact the safety of PD‐1/PD‐L1 inhibitors in cancer patients. Most cancer patients used PD‐1/PD‐L1 inhibitors during COVID‐19 infection (asymptomatic or mild infection) did not experience exacerbation of their underlying condition, nor did they exhibit a substantial increase in toxic side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsImmune Checkpoint InhibitorsSARS-CoV-2HumansMaleFemaleRetrospective StudiesMiddle AgedAgedB7-H1 AntigenImmunotherapyProgrammed Cell Death 1 ReceptorAdultAged, 80 and over

Stichwörter der Autor:innen

COVID‐19 infectionPD‐1/PD‐L1 inhibitorcancerimmune‐related adverse eventspropensity score matching

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Clinical Laboratory, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • The 1st Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Queen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Oncology, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • The 2nd Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.

ORCID-Profile: Long Huang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liao, K., Cheng, J., Hu, Y., Zhang, B., Huang, P., Liu, J., Zhang, W., Hu, H., Bai, X., Qian, Y., Guo, D., Ai, K., Zhu, Y., & Huang, L. (2024). Evaluation of the safety of PD ‐1/ PD ‐ L1 inhibitors for immunotherapy in patients with malignant tumors after COVID ‐19 infection: A single‐center cohort study. Cancer Medicine. https://doi.org/10.1002/cam4.70202

Vancouver

Liao K, Cheng J, Hu Y, Zhang B, Huang P, Liu J, et al. Evaluation of the safety of PD ‐1/ PD ‐ L1 inhibitors for immunotherapy in patients with malignant tumors after COVID ‐19 infection: A single‐center cohort study. Cancer Medicine. 2024. doi:10.1002/cam4.70202

BibTeX
@article{Liao2024,
  author = {Liao, Kaili and Cheng, Jinting and Hu, Yujie and Zhang, Beining and Huang, Peng and Liu, Jie and Zhang, Wenyige and Hu, Huan and Bai, Xinyi and Qian, Yihui and Guo, Daixin and Ai, Kun and Zhu, Yuchen and Huang, Long},
  title = {Evaluation of the safety of PD ‐1/ PD ‐ L1 inhibitors for immunotherapy in patients with malignant tumors after COVID ‐19 infection: A single‐center cohort study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70202}
}
Kostenlos starten →